* If you want to update the article please login/register
Colorectal cancer is an aggressive tumor in which new treatment techniques have had no effect on cure rates and long-term survival. In several experimental tumors, growth hormone-releasing hormone antagonists have been shown to have anticancerogenic effects, but their role in CRC is uncertain. We found that chronic treatment of experimentally induced colitis-associated cancer in mice with a GHRH antagonist of MIAMI class MIA-690 improved survival and gradually halted tumor formation, paralleled by reduced inflammation in colon tissue. In addition, MIA-690 reduced the protein expression of c-Myc, P-AKT, and Bcl-2, as well as upregulated p53 protein expression.
Source link: https://doi.org/10.1016/j.biopha.2021.112554
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions